Emergent Biosolutions Inc (EBS)

$13.86

+0.06

(+0.43%)▲

Live

Performance

  • $13.46
    $14.25
    $13.86
    downward going graph

    2.91%

    Downside

    Day's Volatility :5.57%

    Upside

    2.74%

    downward going graph
  • $1.42
    $14.61
    $13.86
    downward going graph

    89.75%

    Downside

    52 Weeks Volatility :90.28%

    Upside

    5.13%

    downward going graph

Returns

PeriodEmergent Biosolutions IncSector (Health Care)Index (Russel 2000)
3 Months
618.75%
6.5%
0.0%
6 Months
658.24%
7.1%
0.0%
1 Year
92.74%
9.8%
0.0%
3 Years
-77.87%
14.2%
-20.2%

Highlights

Market Capitalization
723.7M
Book Value
$12.67
Earnings Per Share (EPS)
-10.97
PEG Ratio
1.55
Wall Street Target Price
8.0
Profit Margin
-47.69%
Operating Margin TTM
13.25%
Return On Assets TTM
-0.38%
Return On Equity TTM
-60.57%
Revenue TTM
1.2B
Revenue Per Share TTM
22.93
Quarterly Revenue Growth YOY
82.8%
Gross Profit TTM
290.1M
EBITDA
100.2M
Diluted Eps TTM
-10.97
Quarterly Earnings Growth YOY
0.02
EPS Estimate Current Year
-1.22
EPS Estimate Next Year
-1.15
EPS Estimate Current Quarter
-0.83
EPS Estimate Next Quarter
-0.63

Analyst Recommendation

Sell
    11%Buy
    22%Hold
    66%Sell
Based on 9 Wall street analysts offering stock ratings for Emergent Biosolutions Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
2
2
3
Sell
6
6
6

Analyst Forecast

What analysts predicted

Downside of 42.28%

Current $13.86
Target $8.00

Company Financials

FY18Y/Y Change
Revenue
782.4M
↑ 39.5%
Net Income
62.7M
↓ 24.09%
Net Profit Margin
8.01%
↓ 6.72%
FY19Y/Y Change
Revenue
1.1B
↑ 41.36%
Net Income
54.5M
↓ 13.08%
Net Profit Margin
4.93%
↓ 3.08%
FY20Y/Y Change
Revenue
1.6B
↑ 40.63%
Net Income
305.8M
↑ 461.1%
Net Profit Margin
19.66%
↑ 14.73%
FY21Y/Y Change
Revenue
1.8B
↑ 15.26%
Net Income
219.5M
↓ 28.22%
Net Profit Margin
12.24%
↓ 7.42%
FY22Y/Y Change
Revenue
1.1B
↓ 37.47%
Net Income
-223.8M
↓ 201.96%
Net Profit Margin
-19.97%
↓ 32.21%
FY23Y/Y Change
Revenue
1.1B
↑ 0.0%
Net Income
-223.8M
↑ 0.0%
Net Profit Margin
-19.97%
↑ 0.0%
Q4 FY22Q/Q Change
Revenue
330.7M
↑ 37.79%
Net Income
-88.0M
↑ 16.25%
Net Profit Margin
-26.61%
↑ 4.93%
Q1 FY23Q/Q Change
Revenue
165.1M
↓ 50.08%
Net Income
-183.0M
↑ 107.95%
Net Profit Margin
-110.84%
↓ 84.23%
Q2 FY23Q/Q Change
Revenue
337.9M
↑ 104.66%
Net Income
-261.3M
↑ 42.79%
Net Profit Margin
-77.33%
↑ 33.51%
Q3 FY23Q/Q Change
Revenue
270.5M
↓ 19.95%
Net Income
-265.9M
↑ 1.76%
Net Profit Margin
-98.3%
↓ 20.97%
Q4 FY23Q/Q Change
Revenue
276.6M
↑ 2.26%
Net Income
-49.5M
↓ 81.38%
Net Profit Margin
-17.9%
↑ 80.4%
Q1 FY24Q/Q Change
Revenue
300.4M
↑ 8.6%
Net Income
9.0M
↓ 118.18%
Net Profit Margin
3.0%
↑ 20.9%
FY18Y/Y Change
Total Assets
2.2B
↑ 108.32%
Total Liabilities
1.2B
↑ 671.88%
FY19Y/Y Change
Total Assets
2.3B
↑ 4.48%
Total Liabilities
1.2B
↑ 1.83%
FY20Y/Y Change
Total Assets
2.9B
↑ 23.78%
Total Liabilities
1.4B
↑ 15.75%
FY21Y/Y Change
Total Assets
3.0B
↑ 2.63%
Total Liabilities
1.3B
↓ 6.7%
FY22Y/Y Change
Total Assets
3.2B
↑ 7.02%
Total Liabilities
1.8B
↑ 33.1%
FY23Y/Y Change
Total Assets
3.2B
↑ 0.0%
Total Liabilities
1.8B
↑ 0.0%
Q4 FY22Q/Q Change
Total Assets
3.2B
↑ 8.87%
Total Liabilities
1.8B
↑ 22.23%
Q1 FY23Q/Q Change
Total Assets
2.9B
↓ 6.85%
Total Liabilities
1.7B
↓ 2.04%
Q2 FY23Q/Q Change
Total Assets
2.2B
↓ 26.14%
Total Liabilities
1.2B
↓ 30.03%
Q3 FY23Q/Q Change
Total Assets
3.2B
↑ 45.34%
Total Liabilities
1.8B
↑ 45.9%
Q4 FY23Q/Q Change
Total Assets
1.8B
↓ 42.05%
Total Liabilities
1.2B
↓ 33.53%
Q1 FY24Q/Q Change
Total Assets
1.8B
↓ 1.71%
Total Liabilities
1.1B
↓ 3.87%
FY18Y/Y Change
Operating Cash Flow
41.8M
↓ 79.92%
Investing Cash Flow
-897.2M
↑ 258.98%
Financing Cash Flow
788.7M
↓ 1634.41%
FY19Y/Y Change
Operating Cash Flow
188.0M
↑ 349.76%
Investing Cash Flow
-96.9M
↓ 89.2%
Financing Cash Flow
-35.9M
↓ 104.55%
FY20Y/Y Change
Operating Cash Flow
536.0M
↑ 185.11%
Investing Cash Flow
-151.0M
↑ 55.83%
Financing Cash Flow
69.5M
↓ 293.59%
FY21Y/Y Change
Operating Cash Flow
321.1M
↓ 40.09%
Investing Cash Flow
-225.0M
↑ 49.01%
Financing Cash Flow
-141.0M
↓ 302.88%
FY22Y/Y Change
Operating Cash Flow
-34.1M
↓ 110.62%
Investing Cash Flow
-381.3M
↑ 69.47%
Financing Cash Flow
481.2M
↓ 441.28%
Q4 FY22Q/Q Change
Operating Cash Flow
92.8M
↓ 225.41%
Investing Cash Flow
-45.4M
↓ 83.28%
Financing Cash Flow
353.1M
↑ 53.99%
Q1 FY23Q/Q Change
Operating Cash Flow
-184.0M
↓ 298.28%
Investing Cash Flow
-15.1M
↓ 66.74%
Financing Cash Flow
-10.5M
↓ 102.97%
Q2 FY23Q/Q Change
Operating Cash Flow
-114.4M
↓ 37.83%
Investing Cash Flow
257.7M
↓ 1806.62%
Financing Cash Flow
-486.9M
↑ 4537.14%
Q3 FY23Q/Q Change
Operating Cash Flow
60.0M
↓ 152.45%
Investing Cash Flow
-18.9M
↓ 107.33%
Financing Cash Flow
-43.0M
↓ 91.17%

Technicals Summary

Sell

Neutral

Buy

Emergent Biosolutions Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Emergent Biosolutions Inc
Emergent Biosolutions Inc
110.37%
658.24%
92.74%
-77.87%
-68.93%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.56%
2.78%
45.55%
52.55%
67.01%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.53%
11.87%
3.28%
23.35%
23.35%
Zoetis Inc.
Zoetis Inc.
5.77%
-5.62%
-5.85%
-9.99%
57.03%
Viatris Inc.
Viatris Inc.
12.75%
-1.42%
12.21%
-15.03%
-28.03%
Catalent, Inc.
Catalent, Inc.
4.08%
11.91%
19.53%
-48.27%
2.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Emergent Biosolutions Inc
Emergent Biosolutions Inc
69.58
NA
1.55
-1.22
-0.61
0.0
NA
12.67
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.75
39.75
0.44
3.99
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.9
29.9
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.62
34.62
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Emergent Biosolutions Inc
Emergent Biosolutions Inc
Sell
$723.7M
-68.93%
69.58
-47.69%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
67.01%
39.75
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$41.0B
23.35%
29.9
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.0B
57.03%
34.62
27.38%
Viatris Inc.
Viatris Inc.
Hold
$14.2B
-28.03%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.6B
2.08%
211.02
-28.44%

Insights on Emergent Biosolutions Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 270.5M → 300.4M (in $), with an average increase of 5.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -265.9M → 9.0M (in $), with an average increase of 543.6% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 130.5%

Institutional Holdings

  • BlackRock Inc

    13.47%

  • Charles Schwab Investment Management Inc

    7.92%

  • Vanguard Group Inc

    6.51%

  • Avidity Partners Management LP

    3.64%

  • Morgan Stanley - Brokerage Accounts

    2.47%

  • Geode Capital Management, LLC

    2.14%

Company Information

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent

Organization
Emergent Biosolutions Inc
Employees
1600
CEO
Mr. Richard S. Lindahl M.B.A.
Industry
Health Technology

Discover More

FAQs